Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer

References

• Anonymous, Surveillance, epidemiology, and end results (SEER) program public-use data (1973–1998). National Cancer Institute, DCCPS, Surveillance research program, cancer Statistics Branch (April 2001).
   Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U S, 1985–1995 Cancer 1998; 83: 2638–48.
   PubMedGoogle Scholar
• Kebebew E, Clark OH. Differentiated thyroid cancer: "complete" rational approach. World J Surg 2000; 24: 942–51.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Moos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447–63.
   PubMed Web of Science ®Google Scholar
• Clark OH, TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5: 39–47.
   PubMedGoogle Scholar
• Sheils OM, Sweeney EC. TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material. J Pathol 1999; 188: 87–92.
   PubMedGoogle Scholar
• Tanaka K, Inoue H, Milki H, Masuda E, Kitaichi M, Komaki K, et al. Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R. Br J Cancer 1997; 75: 594–9.
   Google Scholar
• Cai WY, Lukes YG, Burch HB, Djuh YY, Carr F, Wartofsky L, et al. Analysis of human TSH receptor gene and RNA transcripts in patients with thyroid disorders. Auto immunity 1992; 13: 43–50.
   Google Scholar
• Goretzki PE, Koob R, Koller T, Simon R, Branscheid D, Clark OH, et al. The effect of thyrotropin and cAMP on DNA synthesis and cell growth of human thyrocytes in monolayer culture. Surgery 1986; 100: 1053–61.
   PubMedGoogle Scholar
• Cetani F, Tonacchera M, Pinchera A, Barsacchi R, Basolo F, Miccoli P, et al. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. J Endocrinol Invest 1999; 22: 273–8.
   PubMedGoogle Scholar
• Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001; 22: 631–56.
   PubMed Web of Science ®Google Scholar
• Gartner R. Thyroid growth in vitro. Exp Clin Endocrinol 1992; 100: 32–5.
   PubMedGoogle Scholar
• Dunhill (Sir) TP. The surgery of the thyroid gland: the Lettsomian lectures. Trans Med Soc Lond 1937; 60: 234–82.
   Google Scholar
• Crile G, Jr. Endocrine dependency of papillary carcinomas of the thyroid. JAMA 1966; 195: 721–4.
   PubMed Web of Science ®Google Scholar
• Crile G, Jr. Changing end results in patients with papillary carcinoma of the thyroid. Surg Gynecol Obstet 1971; 132: 460–8.
   PubMedGoogle Scholar
• Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP, Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977; 56: 171–96.
   PubMed Web of Science ®Google Scholar
• Young RL, Mazzaferri EL, Rohe AJ, Dorfman SG. Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nud Med 1980; 21: 733–7.
   Google Scholar
• Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511–8.
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Andrews W, Kaiser DL. Thyroid cancer: some basic considerations. Am J Surg 1981; 142: 474–9.
   PubMed Web of Science ®Google Scholar
• Cady B, Cohn K, Rossi RL, Sedgwick CE, Meissner WA, Werber J, et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 1983; 94: 978–83.
   PubMed Web of Science ®Google Scholar
• Girelli ME, Busnardo B, Amerio R, Scotton G, Casara D, Betterle C, et al. Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients. Eur J Nud Med 1985; 10: 252–4.
   PubMedGoogle Scholar
• McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WE. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986; 61: 978–96.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987; 14: 315–32.
   PubMed Web of Science ®Google Scholar
• Rossi RL, Cady B, Silverman ML, Wool MS, ReMine SG, Hodge MB, et al. Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch Surg 1988; 123: 569–74.
   PubMedGoogle Scholar
• Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz, MK Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 1063–75.
   PubMed Web of Science ®Google Scholar
• Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990; 160: 344–7.
   PubMedGoogle Scholar
• Mazzaferri EL, Nang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–28.
   PubMed Web of Science ®Google Scholar
• Staunton MD. Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 1994; 20: 613–21.
   PubMedGoogle Scholar
• Jaffiol C, Daures JP, Nsakala N, Guerenova J, Baldet L, Pujol P, et al. Long term follow up of medical treatment of differentiated thyroid cancer. (In French) Ann Endocrinol (Paris) 1995; 56: 119–26.
   PubMedGoogle Scholar
• Sanders LE, Rossi RL. Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J Surg 1995; 19: 642–7.
   PubMedGoogle Scholar
• Herrera MF, Lopez-Graniel CM, Saldana J, Gamboa-Dominguez A, Richaud-Patin Y, Vargas-Vorackova F, et al. Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 1996; 20: 94-9. 32. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318–23.
   PubMedGoogle Scholar
• Esik 0, Tusnady G, Daubner K, Nemeth G, Fuzy M, Szentirmay Z. Survival chance in papillary thyroid cancer in Hungary: individual survival probability estimation using the Markov method. Radiother Oncol 1997; 44: 203–12.
   PubMedGoogle Scholar
• Martins RG, Caplan RH, Lambert PJ, Rooney B, Kisken WA. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. J Am Coll Surg 1997; 185: 388–97.
   PubMedGoogle Scholar
• Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyroid Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Co-operative Registry. Thyroid 1998; 8: 737–44.
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Sugitani I. Postoperative prognosis of intrathyroidal papillary thyroid carcinoma: long-term (35-45 year) follow-up study. Endocr J 1998; 45: 475–84.
   PubMedGoogle Scholar
• Taylor T, Specker B, Robbins J, Sperling M, Ho M, Mn K, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998; 129: 622–7.
   PubMedGoogle Scholar
• Böhm J, Kosma VM, Eskelinen M, Hollmen S, Niskanen M, Tulla H, et al. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Eur J Endocrinol 1999; 141: 460–7.
   PubMedGoogle Scholar
• Kamel N, Gullu S, Dagci llgin S, Corapcioglu D, Tonyukuk Cesur V, Uysal AR, et al. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or meta-stases. Thyroid 1999; 9: 1245–8.
   PubMedGoogle Scholar
• Wang PW, Wang ST, Liu RT, Chien WY, Tung SC, Lu YC, et at Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 4549–53.
   PubMedGoogle Scholar
• Jarzab B, Handkiewicz Junak D, Wloch J, Kalemba B, Roskosz J, Kukulska A, et al. Multivariaw analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nud Med 2000; 27: 833–41.
   PubMedGoogle Scholar
• Csako G, Byrd D, Wesley RA, Sarlis NJ, Skarulis MC, Nieman LK, et al. Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore) 2000; 79: 9–26.
   PubMedGoogle Scholar
• Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health 1996; 17: 1–23.
   PubMed Web of Science ®Google Scholar
• Mulrow C, Cook D. Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions. Philadelphia: American College of Physicians; 1998.
   Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42: 140–5.
   PubMedGoogle Scholar
• Dong BJ. Thyroid disorders. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver; 1996: 47–131.
   Google Scholar
• Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316: 764–70.
   PubMed Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965; 58: 295–300.
   PubMedGoogle Scholar
• Anonymous. SAS/STAT User's Guide: version 6. 4th edn. Cary; SAS Institute, 1990.
   Google Scholar
• Ross DS. Long-term management of differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 719–39.
   PubMed Web of Science ®Google Scholar
• Cady B. Papillary carcinoma of the thyroid. Semin Surg Oncol 1991; 7: 81–6.
   PubMedGoogle Scholar
• Thomas CG, Jr. Role of thyroid stimulating hormone suppression in the management of thyroid cancer. Semin Surg Oncol 1991; 7: 115–9.
   PubMedGoogle Scholar
• Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993; 119: 492–502.
   PubMed Web of Science ®Google Scholar
• McClellan DR, Francis GL. Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 1996; 25: 27–48.
   PubMed Web of Science ®Google Scholar
• Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996; 156: 2165–72.
   PubMed Web of Science ®Google Scholar
• Fuchshuber P, Loree TR, DeLacure MD, Hicks WL, Jr. Differentiated thyroid carcinoma: risk group assignment and management controversies. Oncology 1998 12: 99–106.
   PubMedGoogle Scholar
• PaloYan E, Walker RP, Lawrence AM. Guidelines for the use of radioiodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Surg Oncol Clin N Am 1998; 7: 665–80.
   PubMedGoogle Scholar
• Mazzaferri EL. 1999 NCCN Thyroid Carcinoma Practice Guidelines. National Cancer Center Network Proceedings 1999; 13: 391–442. (also available on Internet site: http:// www.nccn.org; accessibility verified on July 3,2002).
   Google Scholar
• Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 1999; 16: 30–3.
   PubMedGoogle Scholar
• St. Louis JD, ',eight GS, Tyler DS. Follicular neoplasms: the role for observation, fine needle aspiration biopsy, thyroid suppression, and surgery. Semin Surg Oncol 1999; 16: 5–11.
   PubMedGoogle Scholar
• Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: 469–76.
   PubMedGoogle Scholar
• Cobin RH, Gharib H. AACE/AAES. Medical/Surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Prac 2001; 7: 203–20.
   Google Scholar
• Kuriakose MA, Hicks WL, Jr., Loree TR, Yee H. Risk group-based management of differentiated thyroid carcinoma. J R Coll Surg Edinb 2001; 46: 216–23.
   PubMedGoogle Scholar
• van Tol KM, de Vries EG, Dullaart RP, Links TP. Differentiated thyroid carcinoma in the elderly. Crit Rev Oncol Hematol 2001; 38: 79–91.
   PubMedGoogle Scholar
• British Thyroid Association. Guidelines for the management of thyroid cancer. London: Royal College of Physicians; 2002 (also available on Internet site: http://www.british-thyroid-association.org/guidelines.htm; accessibility verified on July 3, 2002).
   Google Scholar
• Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13: 596–611.
   PubMed Web of Science ®Google Scholar
• Hoehing T, Goretzki PE, Duh QY. Follicular thyroid cancer cells: a model of metastatic tumor in vitro. Oncol Rep 2001; 8: 3–8.
   Google Scholar
• Dralle H, Bocker W, Dohler ICD, Schröder S, Haindi H, Geerlings H, et al. Growth and function of thirty-four human benign and malignant thyroid xenografts in untreated nude mice. Cancer Res 1985; 45: 1239–45.
   PubMedGoogle Scholar
• Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid targeted transgenic mice. Oncogene 1999; 18: 3659–65.
   PubMedGoogle Scholar
• Namba H, Yamashita S, Usa T, Kimura H, Yokoyama N, Izumi M, et al. Overexpression of the intact thyrotropin receptor in a human thyroid carcinoma cell line. Endocrinology 1993; 132: 839–45.
   PubMedGoogle Scholar
• Friedland DJ. Evidence-based Medicine: A Framework for Clinical Practice. Stamford: Appleton & Lange; 1998.
   Google Scholar
• Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. 2nd edn. New York: Churchill Livingston q 2000.
   Google Scholar
• Jonklaas J, Sarlis N, Litofsky D, Cooper D, Am K, Bigos S, et al. Both near total/total thyroidecromy (NTT) and thyroid hormone suppression therapy (THST) improve survival of patients with papillary thyroid carcinoma. Proc 73rd Ann Mtg Am Thyroid Assoc 2001; Washington, DC.
   Google Scholar
• Williams JB. Adverse effects of thyroid hormones. Drugs Aging 1997; 11: 460–9.
   PubMed Web of Science ®Google Scholar